Charles River Microbial Solutions Germany GmbH is a subsidiary of Charles River Laboratories International Inc. and is assigned within the group to the Manufacturing Solutions segment; the sole shareholder is Charles River Nederland B.V. Since 2022 the company is headquartered in Kaarst, where the long-term leased site includes approximately a 3,000 square meter production center and a microbiological test laboratory. The CRMS GmbH portfolio comprises the brands Celsis®, Accugenix® and Endosafe®; the company acts as contract manufacturer of Celsis® reagents for CR MSI Ltd (Dublin) and is tasked with R&D for reagent recipes as well as with Accugenix® lab tests and Endosafe® instrument depots. At the Kaarst site CRMS GmbH is certified to ISO9001 and ISO17025 and since 2024 also cGMP-certified, and it employed an average of 64 employees in 2024.
Entwicklung, Produktion und Vertrieb von biotechnologischen Produkten aller Art.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 14530 (as of 22 October 2026)
| Name | Type | City |
|---|---|---|
| Anthony Parfitt | Geschäftsführer(in) | Hungen |
| Thomas Rockel | Geschäftsführer(in) | Düsseldorf |
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 14530 (as of 22 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 30.12.2022 | Registered Seat Change | Kaarst |
| 28.12.2021 | Business Address Change | Detlev-Karsten-Rohwedder-Str. 7, 41564 Kaarst |
| 10.12.2020 | Company Name Change | Charles River Microbial Solutions Germany GmbH |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 25.02.2008 | Share Capital Set | — | 50.000 DM |
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 14530 (as of 22 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€10.5M2 | €633,800 | €14,697,968 | 70 |
| 2024 | Rohergebnis€9.3M2 | €184,996 | €15,011,374 | 64 |
| 2023 | Rohergebnis€8.7M2 | €108,373 | €17,426,465 | 59 |
| 2022 | Rohergebnis€7.4M2 | €521,778 | €16,230,830 | 53 |
| 2021 | ≤ €12M1 | €206,724 | €15,988,083 | 39 |
| 2020 | ≤ €12M1 | -€180,486 | €6,411,345 | 16 |
| 2019 | small company1 | €100,408 | €3,578,958 | 13 |
| 2018 | small company1 | €115,358 | €3,014,671 | 12 |
| 2017 | small company1 | €202,369 | €3,232,538 | 10 |
| 2016 | small company1 | -€29,235 | €2,927,871 | 9 |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Neuss Local Court, HRB 14530 (as of 22 October 2026)
InVivo BioTech Services GmbH
Hennigsdorf · Forschung und Entwicklung im Bereich Biotechnologie
Silony Medical GmbH
Leinfelden-Echterdingen · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Eurofins Agroscience Services Ecotox GmbH
Niefern-Öschelbronn · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,701,867 | 79.7% |
| Depreciation | €1,353,436 | 18.9% |
| Interest & Similar | €99,501 | 1.4% |
